Hypertriglyceridemia is causally linked to the development of ASCVD; furthermore, individuals with severe hypertriglyceridemia (sHTG) – triglyceride (TG) levels ≥ 500 mg/dL – are at high risk of developing of acute pancreatitis. The management of sHTG can be a challenge and includes addressing any modifiable factors, nonpharmacologic measures, and drug therapy. However, in many patients, traditional drug therapies fail to sufficiently lower TG levels and prevent acute pancreatitis. In this program, the faculty will discuss the importance of achieving guideline-recommended treatment goals for patient with sHTG and the potential role of apolipoprotein C-III (APOC3) inhibition as a novel treatment mechanism.

Moderator: Christie M. Ballantyne, MD

Faculty: Pradeep Natarajan, MD, MMSC

Supported by an independent educational grant from Arrowhead Pharmaceuticals, Inc.

Click the link to view the Accreditation and Disclosure details.
img.medscapestatic.com/vim/live/professional_asset…

View the Severe Hypertriglyceridemia Education Hub: Medscape.org/sites/advances/shtg-fcs